Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antisense oligonucleotide therapy corrects splicing in the common Stargardt disease type 1-causing variant ABCA4 c.5461-10T>C.
Kaltak M, de Bruijn P, Piccolo D, Lee SE, Dulla K, Hoogenboezem T, Beumer W, Webster AR, Collin RWJ, Cheetham ME, Platenburg G, Swildens J. Kaltak M, et al. Among authors: de bruijn p. Mol Ther Nucleic Acids. 2023 Feb 18;31:674-688. doi: 10.1016/j.omtn.2023.02.020. eCollection 2023 Mar 14. Mol Ther Nucleic Acids. 2023. PMID: 36910710 Free PMC article.
Clinical utility of circulating tumor DNA in patients with advanced KRASG12C-mutated non-small cell lung cancer treated with sotorasib.
Ernst SM, van Marion R, Atmodimedjo PN, de Jonge E, Mathijssen RHJ, Paats MS, de Bruijn P, Koolen SL, von der Thüsen JH, Aerts JGJV, van Schaik RHN, Dubbink HJ, Dingemans AC. Ernst SM, et al. Among authors: de bruijn p. J Thorac Oncol. 2024 Apr 12:S1556-0864(24)00165-5. doi: 10.1016/j.jtho.2024.04.007. Online ahead of print. J Thorac Oncol. 2024. PMID: 38615940 Free article.
Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis.
Ernst SM, Hofman MM, van der Horst TE, Paats MS, Heijboer FWJ, Aerts JGJV, Dumoulin DW, Cornelissen R, von der Thüsen JH, de Bruijn P, Hoop EO, Mathijssen RHJ, Koolen SLW, Dingemans AC. Ernst SM, et al. Among authors: de bruijn p. EBioMedicine. 2024 Apr;102:105074. doi: 10.1016/j.ebiom.2024.105074. Epub 2024 Mar 19. EBioMedicine. 2024. PMID: 38507877 Free PMC article.
Darolutamide does not interfere with OATP-mediated uptake of docetaxel.
Buck SAJ, Talebi Z, Drabison T, Jin Y, Gibson AA, Hu P, de Bruijn P, de Ridder CMA, Stuurman D, Hu S, van Weerden WM, Koolen SLW, de Wit R, Sparreboom A, Mathijssen RHJ, Eisenmann ED. Buck SAJ, et al. Among authors: de bruijn p. Int J Cancer. 2024 Mar 16. doi: 10.1002/ijc.34922. Online ahead of print. Int J Cancer. 2024. PMID: 38491867
CYP3A4*22 Genotype-Guided Dosing of Kinase Inhibitors in Cancer Patients.
van Eerden RAG, IJzerman NS, van Meekeren M, Oomen-de Hoop E, Guchelaar NAD, Visser AMW, Matic M, van Schaik RHN, de Bruijn P, Moes DAR, Jobse PA, Gelderblom H, Huitema ADR, Steeghs N, Mathijssen RHJ, Koolen SLW; Dutch Pharmacology Oncology Group. van Eerden RAG, et al. Among authors: de bruijn p. Clin Pharmacokinet. 2023 Aug;62(8):1129-1139. doi: 10.1007/s40262-023-01260-4. Epub 2023 Jun 13. Clin Pharmacokinet. 2023. PMID: 37310647 Free PMC article.
Validation of an LC-MS/MS method for simultaneous quantification of abiraterone, enzalutamide and darolutamide in human plasma.
Buck SAJ, de Bruijn P, Ghobadi-Moghaddam-Helmantel IM, Lam MH, de Wit R, Koolen SLW, Mathijssen RHJ. Buck SAJ, et al. Among authors: de bruijn p. J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Jun 1;1225:123752. doi: 10.1016/j.jchromb.2023.123752. Epub 2023 May 26. J Chromatogr B Analyt Technol Biomed Life Sci. 2023. PMID: 37269569 Free article.
141 results